Anais brasileiros de dermatologia最新文献

英文中文

Familial multiple discoid fibromas: clinical features and a brief overview of the literature 家族性多发性盘状纤维瘤：临床特征及文献综述

IF 3.6 4区医学 Q2 DERMATOLOGY

Anais brasileiros de dermatologia

Pub Date : 2026-01-01 DOI: 10.1016/j.abd.2025.501268

Ece Gokyayla , Kamer Gunduz , Peyker Temiz

引用次数: 0

Disseminated miliary lupus on the face: successful treatment with oral dapsone and topical metronidazole 面部弥散性军事性狼疮：口服氨苯砜和局部甲硝唑治疗成功。

IF 3.6 4区医学 Q2 DERMATOLOGY

Anais brasileiros de dermatologia

Pub Date : 2026-01-01 DOI: 10.1016/j.abd.2025.501275

Tania Rita Moreno de Oliveira Fernandes , Itamar Santos , Luciana Lócio Rosado , Pâmela Layra Laguna Dias , Luana da Silva Souza

引用次数: 0

The morbidity of systemic steroids: analyzing its use in bullous pemphigoid 系统性类固醇的发病率：分析其在大疱性类天疱疮中的应用

IF 3.6 4区医学 Q2 DERMATOLOGY

Anais brasileiros de dermatologia

Pub Date : 2026-01-01 DOI: 10.1016/j.abd.2025.501266

Lula María Nieto-Benito , Ricardo Suárez-Fernández

引用次数: 0

Diagnostic value of direct immunofluorescence in oral mucous membrane pemphigoid: a retrospective study 口腔黏膜类天疱疮直接免疫荧光诊断价值的回顾性研究

IF 3.6 4区医学 Q2 DERMATOLOGY

Anais brasileiros de dermatologia

Pub Date : 2026-01-01 DOI: 10.1016/j.abd.2025.501254

Hongjie Jiang , Pan Wei , Zhixiu Xu , Yan Chen , Binbin Li

Background

Mucous membrane pemphigoid (MMP) is an autoimmune blistering disease with heterogeneous clinical manifestations that is hard to diagnose. Direct immunofluorescence (DIF) is critical, but its role in multimodal frameworks is unclear.

Objective

To assess DIF's diagnostic performance in MMP and explore factors affecting its positivity patterns in multimodal workflows.

Methods

We retrospectively analyzed 79 suspected MMP patients, categorizing them into confirmed and non-confirmed groups based on clinical, histopathological, and serological criteria. DIF of perilesional mucosal biopsies showed linear deposits of IgG, IgA, IgM, C3, and fibrinogen along the basement membrane zone (BMZ). Diagnostic efficacy was assessed via ROC curve analysis.

Results

55 cases were confirmed. Histopathology demonstrated subepithelial blisters in 51, with 100% specificity, 92.73% sensitivity (AUC = 0.964, p < 0.05). DIF identified 47 cases, with C3 (63.64%) and IgG (60.00%) most common, showing 85.45% sensitivity, 100% specificity, and 97.87% concordance with histopathology. Disease duration independently predicted positive IgM (p = 0.023).

Study limitations

However, this study is a single-center retrospective study with a limited sample size, which has certain limitations.

Conclusion

DIF, 100% specific, aids histopathology in MMP diagnosis, especially with C3/IgG linear BMZ deposition. Notably, IgM positivity correlates with prolonged disease duration, suggesting DIF efficiency may link to disease stage.

粘膜类天疱疮（MMP）是一种自身免疫性水疱病，临床表现异质性，难以诊断。直接免疫荧光（DIF）至关重要，但其在多模式框架中的作用尚不清楚。目的评价DIF对MMP的诊断效果，探讨其在多模式工作流程中阳性模式的影响因素。方法回顾性分析79例疑似MMP患者，根据临床、组织病理学和血清学标准将其分为确诊组和非确诊组。病灶周围粘膜活检的DIF显示沿基底膜区（BMZ）有IgG、IgA、IgM、C3和纤维蛋白原的线性沉积。通过ROC曲线分析评估诊断效果。结果共确诊55例。51例组织病理学表现为上皮下水疱，特异性100%，敏感性92.73% （AUC = 0.964, p < 0.05）。DIF检出47例，以C3（63.64%）和IgG（60.00%）最常见，敏感性85.45%，特异性100%，与组织病理学一致性97.87%。病程独立预测IgM阳性（p = 0.023）。但本研究为单中心回顾性研究，样本量有限，存在一定的局限性。结论dif具有100%的特异性，有助于组织病理学诊断MMP，特别是C3/IgG线性BMZ沉积。值得注意的是，IgM阳性与疾病持续时间延长相关，这表明DIF效率可能与疾病分期有关。

{"title":"Diagnostic value of direct immunofluorescence in oral mucous membrane pemphigoid: a retrospective study","authors":"Hongjie Jiang , Pan Wei , Zhixiu Xu , Yan Chen , Binbin Li","doi":"10.1016/j.abd.2025.501254","DOIUrl":"10.1016/j.abd.2025.501254","url":null,"abstract":"<div><h3>Background</h3><div>Mucous membrane pemphigoid (MMP) is an autoimmune blistering disease with heterogeneous clinical manifestations that is hard to diagnose. Direct immunofluorescence (DIF) is critical, but its role in multimodal frameworks is unclear.</div></div><div><h3>Objective</h3><div>To assess DIF's diagnostic performance in MMP and explore factors affecting its positivity patterns in multimodal workflows.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 79 suspected MMP patients, categorizing them into confirmed and non-confirmed groups based on clinical, histopathological, and serological criteria. DIF of perilesional mucosal biopsies showed linear deposits of IgG, IgA, IgM, C3, and fibrinogen along the basement membrane zone (BMZ). Diagnostic efficacy was assessed via ROC curve analysis.</div></div><div><h3>Results</h3><div>55 cases were confirmed. Histopathology demonstrated subepithelial blisters in 51, with 100% specificity, 92.73% sensitivity (AUC = 0.964, p < 0.05). DIF identified 47 cases, with C3 (63.64%) and IgG (60.00%) most common, showing 85.45% sensitivity, 100% specificity, and 97.87% concordance with histopathology. Disease duration independently predicted positive IgM (p = 0.023).</div></div><div><h3>Study limitations</h3><div>However, this study is a single-center retrospective study with a limited sample size, which has certain limitations.</div></div><div><h3>Conclusion</h3><div>DIF, 100% specific, aids histopathology in MMP diagnosis, especially with C3/IgG linear BMZ deposition. Notably, IgM positivity correlates with prolonged disease duration, suggesting DIF efficiency may link to disease stage.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"101 1","pages":"Article 501254"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146074039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel sporadic c.2687G>T (p.Gly896Val) CYLD mutation in multiple trichoepitheliomas c.2687G>T (p.Gly896Val) CYLD在多发毛上皮瘤中的突变

IF 3.6 4区医学 Q2 DERMATOLOGY

Anais brasileiros de dermatologia

Pub Date : 2026-01-01 DOI: 10.1016/j.abd.2025.501282

Ahmet Uğur Atılan, Niyazi Cetin

引用次数: 0

Letter to the Editor regarding: “Pre-and post-analytical guidelines for the microscopic diagnosis of melanoma: recommendations from the Brazilian Society of Pathology” 致编辑的信：“黑素瘤显微诊断的前后分析指南：来自巴西病理学会的建议”

IF 3.6 4区医学 Q2 DERMATOLOGY

Anais brasileiros de dermatologia

Pub Date : 2026-01-01 DOI: 10.1016/j.abd.2025.501271

José Antonio Jabur da Cunha , Roberto Gomes Tarle , Glaysson Tassara Tavares

引用次数: 0

Comparison of meglumine antimoniate versus miltefosine in the treatment of new world cutaneous leishmaniasis: a systematic review and meta-analysis 锑酸甲氨胺与米替福辛治疗新世界皮肤利什曼病的比较：系统回顾和荟萃分析

IF 3.6 4区医学 Q2 DERMATOLOGY

Anais brasileiros de dermatologia

Pub Date : 2026-01-01 DOI: 10.1016/j.abd.2025.501253

Ana Carolina Putini Vieira, Fernanda Cronemberger Lins, Arianne Costa Baquião

Background

Cutaneous Leishmaniasis (CL) affects up to 1.2 million people annually, mainly in resource-limited regions. Meglumine antimoniate, the standard treatment, is limited by systemic toxicity, injectable administration, and increasing resistance. Miltefosine, an oral alternative, offers practical advantages, although comparative efficacy and safety data remain inconsistent.

Objective

To compare the efficacy and safety of miltefosine versus meglumine antimoniate for New World CL.

Methods

The authors systematically searched PubMed, Embase, Scopus, and the Cochrane Library for randomized controlled trials directly comparing miltefosine and meglumine antimoniate. Risk Ratios (RRs) with 95% Confidence Intervals (95% CIs) were calculated using random-effects models. Heterogeneity was assessed with the I² statistic. Risk of bias was evaluated using the Cochrane RoB-2 tool. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach.

Results

Eight trials involving 898 patients (502 treated with miltefosine, 396 with meglumine antimoniate) were included. Miltefosine showed significantly higher cure rates at two months (RR = 0.83; 95% CI: 0.71–0.98; I² = 0%). Differences at six months were not statistically significant. Gastrointestinal side effects were more frequent with miltefosine, whereas hepatic enzyme elevations, arthralgia (RR = 10.08; 95% CI: 2.36–43.12), and fever (RR = 2.98; 95% CI: 1.53–5.80) were more common with meglumine antimoniate.

Study Limitations

High heterogeneity, short follow-up, small sample sizes, and interstudy variability may limit precision.

Conclusion

Miltefosine shows superior early response and a safer systemic profile. However, the certainty of evidence, as assessed by GRADE, ranged from very low to high across outcomes, and long-term data remain limited, highlighting the need for further high-quality studies with extended follow-up.

皮肤利什曼病每年影响多达120万人，主要发生在资源有限的地区。标准的治疗方法氨铵甲胺，由于全身毒性、注射给药和耐药性增加而受到限制。口服替代药物米特福辛具有实际优势，尽管相对疗效和安全性数据仍不一致。目的比较米地福辛与锑酸甲氨胺治疗新世界CL的疗效和安全性。方法系统检索PubMed、Embase、Scopus和Cochrane图书馆，直接比较米替福辛和锑酸meglumine的随机对照试验。采用随机效应模型计算95%置信区间（95% ci）的风险比（RRs）。异质性评价采用I²统计量。使用Cochrane rob2工具评估偏倚风险。采用推荐、评估、发展和评价分级（GRADE）方法评估证据的确定性。结果纳入8项试验，共纳入898例患者（502例使用米地福辛，396例使用甲氨苄胺）。米替福辛在2个月的治愈率显著提高（RR = 0.83; 95% CI: 0.71-0.98; I2 = 0%）。6个月时差异无统计学意义。米替福辛的胃肠道副作用更为常见，而氨铵甲氨胺的肝酶升高、关节痛（RR = 10.08; 95% CI: 2.36-43.12）和发热（RR = 2.98; 95% CI: 1.53-5.80）更为常见。研究局限性：高异质性、短随访、小样本量和研究间的可变性可能限制精度。结论米替福辛具有较好的早期疗效和较安全的全身特征。然而，根据GRADE评估，证据的确定性从非常低到高不等，长期数据仍然有限，强调需要进一步的高质量研究和长期随访。

{"title":"Comparison of meglumine antimoniate versus miltefosine in the treatment of new world cutaneous leishmaniasis: a systematic review and meta-analysis","authors":"Ana Carolina Putini Vieira, Fernanda Cronemberger Lins, Arianne Costa Baquião","doi":"10.1016/j.abd.2025.501253","DOIUrl":"10.1016/j.abd.2025.501253","url":null,"abstract":"<div><h3>Background</h3><div>Cutaneous Leishmaniasis (CL) affects up to 1.2 million people annually, mainly in resource-limited regions. Meglumine antimoniate, the standard treatment, is limited by systemic toxicity, injectable administration, and increasing resistance. Miltefosine, an oral alternative, offers practical advantages, although comparative efficacy and safety data remain inconsistent.</div></div><div><h3>Objective</h3><div>To compare the efficacy and safety of miltefosine versus meglumine antimoniate for New World CL.</div></div><div><h3>Methods</h3><div>The authors systematically searched PubMed, Embase, Scopus, and the Cochrane Library for randomized controlled trials directly comparing miltefosine and meglumine antimoniate. Risk Ratios (RRs) with 95% Confidence Intervals (95% CIs) were calculated using random-effects models. Heterogeneity was assessed with the I² statistic. Risk of bias was evaluated using the Cochrane RoB-2 tool. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach.</div></div><div><h3>Results</h3><div>Eight trials involving 898 patients (502 treated with miltefosine, 396 with meglumine antimoniate) were included. Miltefosine showed significantly higher cure rates at two months (RR = 0.83; 95% CI: 0.71–0.98; <em>I</em><sup>2</sup> = 0%). Differences at six months were not statistically significant. Gastrointestinal side effects were more frequent with miltefosine, whereas hepatic enzyme elevations, arthralgia (RR = 10.08; 95% CI: 2.36–43.12), and fever (RR = 2.98; 95% CI: 1.53–5.80) were more common with meglumine antimoniate.</div></div><div><h3>Study Limitations</h3><div>High heterogeneity, short follow-up, small sample sizes, and interstudy variability may limit precision.</div></div><div><h3>Conclusion</h3><div>Miltefosine shows superior early response and a safer systemic profile. However, the certainty of evidence, as assessed by GRADE, ranged from very low to high across outcomes, and long-term data remain limited, highlighting the need for further high-quality studies with extended follow-up.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"101 1","pages":"Article 501253"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145922437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the Editor regarding: “Pre- and post-analytical guidelines for the microscopic diagnosis of melanoma: recommendations from the Brazilian Society of Pathology” – Reply 致编辑的信：“黑素瘤显微诊断的前后分析指南：巴西病理学会的建议”-回复。

IF 3.6 4区医学 Q2 DERMATOLOGY

Anais brasileiros de dermatologia

Pub Date : 2026-01-01 DOI: 10.1016/j.abd.2025.501272

José Cândido Caldeira Xavier-Júnior , Karina Munhoz de Paula Alves Coelho , Mariana Petaccia de Macedo , Rute Facchini Lellis , Nathanael de Freitas Pinheiro Junior , Robledo Fonseca Rocha , Comitê de Dermatopatologia da Sociedade Brasileira de Patologia

引用次数: 0

Comment on “The relationship of FricTest® responses with an urticaria activity score, urticaria control test and quality of life scales in patients with symptomatic dermographism” 对“症状性皮肤统计学患者的FricTest®反应与荨麻疹活动评分、荨麻疹控制测试和生活质量量表的关系”的评论

IF 3.6 4区医学 Q2 DERMATOLOGY

Anais brasileiros de dermatologia

Pub Date : 2026-01-01 DOI: 10.1016/j.abd.2025.501285

Prajnasini Satapathy , Rachana Mehta , Ranjana Sah

引用次数: 0

Comparing the genetic and serum expression of LL-37 Antimicrobial Peptide in pemphigus vulgaris and pemphigus foliaceus patients 寻常型天疱疮和叶状天疱疮患者LL-37抗菌肽基因及血清表达的比较

IF 3.6 4区医学 Q2 DERMATOLOGY

Anais brasileiros de dermatologia

Pub Date : 2026-01-01 DOI: 10.1016/j.abd.2025.501262

Fatma Dhaffouli , Nesrine Elloumi , Khadija Sellami , Emna Bahloul , Safa Tahri , Hamida Turki , Hend Hachicha , Olfa Abida

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Anais brasileiros de dermatologia

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀